Stages on the way to breast cancer

Journal of Pathology

Volumn 199, Issue 1, 2003, Pages 1-3

  Going, J J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Atypia; Breast; Diffirentiation; Hyperplasia; Immunohistochemistry

Indexed keywords

ALPHA ACTIN; CYTOKERATIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CANCER RISK; CELL COUNT; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; DISEASE ASSOCIATION; EPITHELIUM; EPITHELIUM HYPERPLASIA; HUMAN; IMMUNOHISTOCHEMISTRY; MYOEPITHELIUM; PAGET NIPPLE DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; FEMALE; HUMANS; HYPERPLASIA; KERATINS; LOSS OF HETEROZYGOSITY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; PRECANCEROUS CONDITIONS;

EID: 0037222795     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1281     Document Type: Article

References (27)

1. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157.
2. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002; 196: 280-286.
3. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
4. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998; 122: 1053-1055.
5. Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratton MR, Sloane JP. Detection of allefic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest 1996; 74: 129- 135.
6. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998; 90: 697-703.
7. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol 1999; 189: 496-503.
8. Cornelio DA, Schmid-Braz AT, Cavalli LR, Lima RS, Ribeiro EM, Cavalli IJ. Clonal karyotypic abnormalities in gynecomastia. Cancer Genet Cytogenet 1999; 115: 128-133.
9. Micale MA, Visscher DW, Gulino SE, Wolman SR. Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 1994; 25: 29-35.
10. Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001; 7: 2410-2414.
11. Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol 2000; 9: 14-19.
12. Werner M, Mattis A, Aubele M, et al. 20q 13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast. Virchows Arch 1999; 435: 469-472.
13. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 2001; 195: 415-421.
14. Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000; 37: 232-240.
15. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002; 198: 458-467.
16. Kordon EC, Smith GH. An entire functional mammary gland may comprise the progeny from a single cell. Development 1998; 125: 1921-1930.
17. Chepko G, Smith GH. Mammary epithelial stem cells: our current understanding. J Mammary, Gland Biol Neoplasia 1999; 4: 35-52.
18. Li P, Barraclough R, Fernig DG, Smith JA, Rudland PS. Stem cells in breast epithelia. Int J Exp Pathol 1998; 79: 193-206.
19. Pechoux C, Gudjonsson T, Ronnov-Jessen L, Bissell MJ, Petersen OW. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev Biol 1999; 206: 88-99.
20. Smith GH, Chepko G. Mammary epithelial stem cells. Microsc Res Tech 2001; 52: 190-203.
21. Stingl J, Eaves CJ, Zandieh I, Emerman JT. Characterization of' bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat 2001; 67: 93-109.
22. Buerger H, Simon R, Schafer KL, et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol 2000; 53: 118-121.
23. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987-4991.
24. Shoker BS, Jarvis C, Clarke RB, et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999; 155: 1811-1815.
25. Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 2002; 160: 597-604.
26. Gobbi H, Dupont WD, Simpson JF, et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999; 91: 2096-2101.
27. Hall PA, Going JJ. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 1999; 35: 489-494.